Enliven Therapeutics, Inc. (ELVN) vs Parabilis Medicines, Inc. (PBLS)
A side-by-side comparison of Enliven Therapeutics, Inc. and Parabilis Medicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ELVN
Enliven Therapeutics, Inc.
$42.06HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
PBLS
Parabilis Medicines, Inc.
$28.57HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — ELVN vs PBLS
growth of $100 · dividends reinvested · last 1yELVN +31.0% (+31.0%/yr)PBLS +47.7% (+47.7%/yr)PBLS compounded faster over this window
ELVN PBLS
ELVN vs PBLS: by the numbers
- •PBLS is the larger company ($3.33B vs $3.00B market cap).
Metrics side by side
Valuation
| Metric | ELVN | PBLS |
|---|---|---|
| P/B ratio | 3.36 | 3.18 |
Profitability
| Metric | ELVN | PBLS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -11.83% | N/A |
| ROIC | -13.88% | -409.85% |
Growth (annualized)
| Metric | ELVN | PBLS |
|---|---|---|
| Total return CAGR (5Y) | 24.57% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.